IPO registrations (S-1, F-1) · Registrants
Achilles Therapeutics plc
- SEC CIK
- 1830749 · filings on EDGAR ↗
- Former names
- Achilles Therapeutics Ltd (2020–2021)
- Registration
- Form F-1, first filed 2021-03-01, last 2021-03-29; 1 initial registration, 3 amendments
- Outcome
- Final prospectus filed 2021-03-31; declared effective 2021-03-30
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- X0
- Business address
- 245 HAMMERSMITH ROAD, London, X0 W6 8PW
- EDGAR entity type
- other
- Insiders and CEO pay
- Achilles Therapeutics plc on the corporate pages
Offering terms
- Proposed price range
- $17.00–$19.00 per ADS (F-1/A filed 2021-03-29)
- Final price
- $18.00 per ADS, within the range (424B4 filed 2021-03-31, an initial public offering)
- Shares sold
- 9,750,000
- Gross proceeds
- $175,500,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ACHL
- Lead underwriters
- J.P. Morgan (3,412,500 shares); BofA Securities (3,412,500 shares); Piper Sandler (1,706,250 shares)
- Syndicate
- Chardan (487,500); Oppenheimer (390,000); Kempen & Co (341,250)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: ACHILLES THERAPEUTICS PLC EXACT (CIK (EXACT))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-03-01 | F-1 | F-1 (foreign registration) | Achilles Therapeutics plc | 0001193125-21-063774 ↗ |
| 2021-03-10 | F-1/A | F-1/A (amendment) | Achilles Therapeutics plc | 0001193125-21-076206 ↗ |
| 2021-03-25 | F-1/A | F-1/A (amendment) | Achilles Therapeutics plc | 0001193125-21-093358 ↗ |
| 2021-03-29 | F-1/A | F-1/A (amendment) | Achilles Therapeutics plc | 0001193125-21-098251 ↗ |
| 2021-03-30 | EFFECT | EFFECT (declared effective) | Achilles Therapeutics plc | 9999999995-21-001207 ↗ |
| 2021-03-31 | 424B4 | 424B4 (final prospectus) | Achilles Therapeutics plc | 0001193125-21-102495 ↗ |
| 2022-11-17 | EFFECT | EFFECT (declared effective) | Achilles Therapeutics plc | 9999999995-22-003336 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-03-29 | F-1/A | registration statement | $17.00–$19.00 | 9,750,000 | - | Nasdaq ACHL | 6 | primary document; range, shares headline, cover names 6 | document ↗ | |
| 2021-03-31 | 424B4 | final prospectus | $18.00 | 9,750,000 | $175,500,000 | Nasdaq ACHL | 6 | primary document; price sentence, shares headline, proceeds table, underwriting table 6, cover names 6 | document ↗ |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | ACHILLES THERAPEUTICS PLC | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), X0 first:
- Abcam plc X0
- Immunocore Holdings plc X0
- Autolus Therapeutics plc X0
- Orchard Therapeutics plc X0
- Freeline Therapeutics Holdings plc X0
- Gyroscope Therapeutics Holdings plc X0
- OKYO Pharma Ltd X0
- Exscientia plc X0
- TC BioPharm (Holdings) plc X0
- BioNTech SE 2M
In other datasets, the same topic (Health) in X0:
- Form D issuer: Abcam plc (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health